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Leishmaniasis are a group of diseases with different clini-
cal manifestations (cutaneous, mucocutaneous and visceral),
which represent a severe public health problem in some trop-
ical and subtropical areas. They are often disfiguring and
sometimes fatal protozoan diseases affecting over 12 million
people worldwide and, for which, there is still no effective
vaccine. 
Chemotherapy remains the most effective control measure
for leishmaniasis. However, current drugs, like sodium sti-
bogluconate (Pentostam®) or N-methylglucamine (Glucan-
time®), are expensive and variable in their efficacy. They also
require protracted courses of parenteral administration and
have toxic side effects,1) which often result in the interruption
of treatment. Furthermore, the increasing resistance to anti-
monial drugs in many parts of the world clearly indicates the
need for a more effective and safer chemotherapeutic ap-
proach. 
Based on ethnomedical information obtained from popula-
tions which use traditional remedies, new antileishmanial
products like quinoline alkaloids have been discovered dur-
ing the last decade.2) Improving efficacy of chemotherapeutic
treatment by introducing structural modifications within
these new drugs constitutes a major goal.
Because the introduction of fluorine into molecules modi-
fies the physiological activity of the resulting compounds, the
development of fluorinated analogues has received increas-
ing attention in recent years. We wish to present the method-
ology we used in the preparation of 2-propyltrifluoromethyl-
quinolines 1 and the chemical transformations of trifluo-
romethylquinaldines 2 into 2-alkenyl and 2-epoxypropyltri-
fluoromethylquinolines via the corresponding aldehydes.
Preliminary in vitro evaluation of these synthetic compounds
will be presented.
Chemistry In a previous paper,3) Song has described the
synthesis of 6- and 7-fluorinated quinaldines by the Skraup
reaction from the corresponding fluorinated anilines. We
have revisited this reaction with poorly nucleophilic tri-
fluoroanilines which were converted into 2-propyltrifluo-
romethylquinolines 1a—d. The best yields were obtained by
changing p-chloranil with air flow as the oxidant in refluxing
butanol. The use of m-trifluoromethylaniline gave access to
1b and 1d in a 10/1 ratio (Chart 1).
In order to introduce a trifluoromethyl group on the pyri-
dine ring of the quinoline skeleton, we have first studied the
cyclization of the trifluoromethylenaminone 4 (Chart 1).
Condensation of 1-pentynyllithium with 1,1-difluoroethyltri-
fluoroacetate in the presence of BF3–Et2O gave access to 3
which was transformed into 4 after a Michael reaction with
aniline. Initial attempts at cyclization of 4 using a variety of
Lewis acids (AlCl3, BF3–Et2O or TiCl4) failed, resulting in
only the recovery of starting material. The use of trifluo-
roacetic or sulfuric acid leads to traces of quinoline 1e in a
mixture of tarry matters. The yield was finally substantially
improved in polyphosphoric acid (24 h, reflux, 63%).
To prepare the 2-propyl-3-trifluoromethylquinoline 1f, we
first synthesized the 2-propyl-3-iodoquinoline 5 by the use of
a large excess of propyllithium on 3-aminoquinoline, fol-
lowed by diazotisation and subsequent treatment with potas-
sium iodide. Considerable attention has been devoted to find-
ing methods for introducing the trifluoromethyl group onto
aromatic halide compounds. For example, Kobayashi4) pre-
pared a trifluoromethylcopper species by the reaction of CF3I
with activated copper in DMF, Matsui5) has developed a con-
venient trifluoromethylation of aromatic halides with sodium
trifluoroacetate, and Fuchikami6) used the (CF3SiMe3/KF/
CuI) system for trifluoromethylation of halides. Best results
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Chart 1
were obtained in the preparation of 1f by using difluorocar-
benes generated from methylchlorodifluoroacetate in the
presence of KF and CuI in DMF7) (Chart 1).
To prepare 2-propenyltrifluoromethylquinolines 7 and 2-
epoxypropyl-trifluoromethylquinolines 8, we first synthesised
the quinaldines 2 as described for 1. The transformation of
quinaldines into 2-quinolinecarboxaldehydes 6 with SeO2 in
dioxane was not affected by the electron-withdrawing effect
of the trifluoromethyl group.
Wittig olefination with ethyltriphenylphosphonium iodide
afforded 2-propenyltrifluoromethylquinolines 7 as single E
isomers in good yields. To prepare 2-epoxypropylpropyle-
neoxyde-trifluoromethylquinolines 8 as fluorinated analogues
of the natural product isolated by Fournet,2) we used the reac-
tion of the sulfur ylide generated from ethyldiphenylsulfoni-
umtetrafluoroborate on 2-trifluoromethylquinolinecarbox-
aldehydes 6 as previously described by Brochet8) and us.9)
Epoxides were then obtained in good yields as a separable
mixture of Z and E isomers (1/1). The stereochemistry of
these epoxides was determinated by studying their 1H-NMR
spectra : measure of JH29–H39 (4.5 and 2 Hz for Z and E isomers
respectively), NOE experiments and comparison with the 1H-
NMR spectra of the E antileishmanial natural epoxide.9)
We have also synthesized the 2-(3,3,3-trifluoropropyl)
quinoline 9 by the use of a Grignard reagent on N-quinoli-
neoxide, but a more efficient way consisted in the preparation
of the lithium salt of 3-bromo-1,1,1-trifluoromethylpropane
that reacts with quinoline to give 9 in a 60 % yield (Chart 3).
Antileishmanial Activity Various in vitro tests were
used to assess the antileishmanial activity of 2-substituted tri-
fluoromethylquinolines. These tests have been done at both
the Pasteur Institute (Paris, France) and at the Swiss Tropical
Institute (Basel, Switzerland). They were based upon the use
of axenic amastigotes and peritoneal or bone marrow-derived
mouse macrophages infected with amastigotes from different
Leishmania species, including L. donovani (MHOM/ET/
1967/L82), L. infantum (IPZ 229/1/89) and L. amazonensis
(MPRO/BR/1972/M1841).
The reference drugs used were sodium stibogluconate, am-
photericin B, allopurinol or allopurinol riboside and leucine-
methyl ester (L. amazonensis). For all the tests, these prod-
ucts showed consistent and reproductible leishmanicidal ac-
tivity proving the validity of our assays.
Unfortunately, the various molecular changes made on nat-
ural products did not further improve their activity. On the
contrary, for all the compounds we have tested, i.e., 2-alkyl,
2-alkenyl and 2-epoxypropyl-trifluoromethylquinolines, we
have noted a decrease of antileishmanial activity compared to
control drugs and natural products. For example, from a con-
centration of 1.5 mg/ml, the natural 2-prop-1-enylquinoline
showed a leishmanicidal activity against Leishmania amazo-
nensis; in contrast, trifluoromethylated analogues were only
efficient at a concentration of 50 mg/ml. The 2-propylquino-
line was active at 12.5 mg/ml, whereas 1f (the most efficient
compound 1) was only active at 25 mg/ml. The 2-epoxypropyl-
trifluoromethylquinolines were poorly active around 100
mg/ml.
Preliminary works point out that natural quinolines, such
as 2-propylquinoline, are transformed in liver cells into oxi-
dized metabolits.10) Moreover, these metabolits should be the
active drugs because the natural 2-propylquinoline is more
efficient by oral administration than by parenteral route.11)
The introduction of a trifluoromethyl substituent must pre-
vent or slow down this oxidizing mechanism which could ex-
plain the above antileishmanial results. Introduction of elec-
tro-donnor groups on 2-substituted-quinolines should give
highly promising results.
Experimental 
19F-NMR chemical shifts are reported in ppm, negative upfield relative to
internal CFCl3, 
1H- and 13C-NMR chemical shifts are reported in ppm, posi-
tive downfield relative to internal TMS. Spectra were recorded on Bruker
AC 200P spectrometer (188, 200 and 50 MHz for 19F, 1H and 13C, respec-
tively). Analytical thin-layer chromatography was performed on Merck silica
gel 60F254 glass precoated plates. All liquid chromatography separations
were performed using Merck silica gel 60 (230—400 mesh ASTM). Ele-
mental analyses12) were performed by the Service de microanalyses, Centre
d’Etudes Pharmaceutiques, Châtenay-Malabry, France, with a Perkin Elmer
2400 analyzer.
2-Propyltrifluoromethylquinolines 1a—d A mixture of trifluoro-
methylaniline (30 mmol), butanol (40 ml), HCl 12 N (10 ml) was heated
under reflux and then trans-hexenal (150 mmol) was slowly added. The re-
sulting solution was heated under reflux and under draught for 8 h. The
cooled reaction mixture was made alkaline with KOH and extracted with
CH2Cl2. After drying, and the removal of the solvent, chromatographic pu-
rification on silica gel afforded the desired quinolines.
2-Propyl-8-trifluoromethylquinoline 1a: 52%. 1H-NMR (CDCl3) d : 1.00
(3H, t, J57.9 Hz), 1.90 (2H, m), 3.00 (2H, t, J57.9 Hz), 7.35 (1H, d, J58.4
Hz), 7.50 (1H, t, J57.9 Hz), 7.85 (1H, d, J57.9 Hz), 8.10 (1H, d, J57.9 Hz),
8.35 (1H, d, J58.4 Hz). 19F-NMR (CDCl3) d : 260.31 (CF3, s). 13C-NMR
(CDCl3) d : 13.8, 22.1, 41.1, 122.3, 124.1, 127.0, 127.2 (q, J529 Hz), 127.5
(q, J55.4 Hz), 129.7 (q, J5268 Hz), 131.9, 135.8, 144.6, 163.7.
2-Propyl-7-trifluoromethylquinoline 1b: 56%. 1H-NMR (CDCl3) d : 1.00
(3H, t, J57.3 Hz), 1.90 (m, 2H), 3.00 (2H, t, J57.3 Hz), 7.40 (1H, d, J58.5
Hz), 7.65 (1H, dd, J58.5 Hz, J51.4 Hz), 7.85 (1H, d, J58.5 Hz), 8.10 (1H,
d, J58.5 Hz), 8.35 (1H, d, J51.4 Hz). 19F-NMR (CDCl3) d : 262.81 (CF3,
s). 13C-NMR (CDCl3) d : 13.9, 22.9, 41.2, 121.3, 123.3, 124.8 (q, J5242
Hz), 126.8, 128.2, 128.6, 131.0, 135.8, 146.9, 164.5.
2-Propyl-6-trifluoromethylquinoline 1c: 51%. 1H-NMR (CDCl3) d : 0.95
(3H, t, J57.3 Hz), 1.65 (2H, m), 2.45 (2H, t, J57.3 Hz), 7.30 (1H, d, J58.4
Hz), 7.75 (1H, d, J58.9 Hz), 8.00 (3H, m). 19F-NMR (CDCl3) d : 262.42
(CF3, s). 
13C-NMR (CDCl3) d : 13.8, 22.9, 41.2, 122.5, 124.1 (q, J5270.4
Hz), 124.8, 125.3, 125.5, 127.5 , 130.0, 136.6, 148.8, 165.3.
2-Propyl-5-trifluoromethylquinoline 1d: 6%. 1H-NMR (CDCl3) d : 1.00
(3H, t, J57.5 Hz), 1.85 (2H, m), 3.00 (2H, t, J57.9 Hz), 7.40 (1H, d, J58.8
Hz), 7.70 (1H, t, J57.9 Hz), 7.85 (1H, d, J57.9 Hz), 8.20 (1H, d, J58.8 Hz),
8.40 (1H, d, J57.9 Hz). 19F-NMR (CDCl3) d : 259.44 (CF3, s). 13C-NMR
(CDCl3) d : 13.8, 22.9, 41.0, 122.6, 124.1, 124.3 (q, J5274 Hz), 126.1 (q,
J532 Hz), 127.0, 127.5 132.4, 133.7, 148.1, 163.7.
April 2001 481
Chart 2
Chart 3
2-Methyl-trifluoromethylquinolines 2a,b These compounds were pre-
pared as described above by changing trans-butenal to trans-hexenal.
2-Methyl-8-trifluoromethylquinoline 2a: 51%. 1H-NMR (CDCl3) d : 2.85
(3H, s), 7.35 (1H, d, J59 Hz), 7.50 (1H, t, J58.0 Hz), 7.95 (1H, d, J59 Hz),
8.05 2H, m). 19F-NMR (CDCl3) d : 260.22 (CF3, s). 13C-NMR (CDCl3) d :
25.8, 122.7, 124.1, 124.3 (q, J5274 Hz), 126.5 (q, J529 Hz), 126.8, 127.5
(q, J55.3 Hz), 132.0, 135.9, 144.5, 160.2.
2-Methyl-6-trifluoromethylquinoline 2b: 55%. 1H-NMR (CDCl3) d : 2.77
(3H, s), 7.36 (1H, d, J58.8 Hz), 7.80 (1H, dd, J58.8 Hz, J52.3 Hz), 8.10
(3H, m). 19F-NMR (CDCl3) d : 262.42 (CF3, s). 13C-NMR (CDCl3) d : 25.5,
123.2, 125.0, 125.1 (q, J5278 Hz), 125.3, 125.5 (q, J55.1 Hz), 128.1 (q,
J529 Hz), 129.8, 136.7, 148.9, 161.5 
1,1,1-Trifluoromethylhept-3-yn-2-one 3 Butyllithium (1.6 M in hexane,
46 ml, 74 mmol) was added to pent-1-yne (4.59 g, 67 mmol) in THF (120 ml)
at 278 °C and this mixture was stirred at this temperature for 30 min. 2,2-di-
fluoroethyl trifluoroacetate (13.35 g, 75 mmol) in THF (100 ml) was added
followed immediately by boron trifluoride-diethyl ether complex (11.3 g, 80
mmol). The mixture was stirred at 278 °C for 90 min. Saturated aqueous
ammonium chloride (40 ml) was added and the solution was allowed to
warm to ambient temperature. The THF was evaporated and the residue,
taken up in dichloromethane, was washed with water and twice with brine
and dried. The residue was then purified by silica gel column chromatogra-
phy to give 3 (9.1 g , 85%).
1H-NMR (CDCl3) d : 1.00 (3H, t, J57.3 Hz), 1.65 (2H, m), 2.45 (2H, t,
J57.3 Hz). 19F-NMR (CDCl3) d : 278.51 (CF3, s).
1,1,1-Trifluoromethyl-4-phenylaminohept-3-en-2-one 4 Aniline (5.3
g, 56.9 mmol) and 3 (9.34 g, 57 mmol) were stirred in methanol (50 ml) for
24 h at ambient temperature. After evaporation of the solvent, the residue
was purified by silica gel column chromatography to give 4 (11.23 g, 77%).
1H-NMR (CDCl3) d : 0.80 (3H, t, J57.3 Hz), 1.20 (1H, bs), 1.50 (2H, m),
2.25 (2H, t, J57.3 Hz), 5.50 (1H, s), 7.00—7.40 (5H, m). 19F-NMR (CDCl3)
d : 262.65 (CF3, s).
2-Propyl-4-trifluoromethylquinoline 1e 4 (2 g, 7.8 mmol) and polyphos-
phoric acid (10 ml) were stirred under reflux for 24 h. The cooled reac-
tion mixture was basified with KOH (1 N, 40 ml) and extracted with
dichloromethane. After drying, and the removal of the solvent, chromato-
graphic purification on silica gel afforded 1e (1.17 g, 63%).
1H-NMR (CDCl3) d : 1.00 (3H, t, J57.3 Hz), 1.85 (2H, m), 2.95 (2H, t,
J57.3 Hz), 7.50 (2H, m), 7.70 (1H, m), 8.10 (2H, m). 19F-NMR (CDCl3) d :
261.81 (CF3, s). 
13C-NMR (CDCl3) d : 13.7, 22.8, 41.1, 118.2, 121.3, 123.6
(q, J5273 Hz), 123.7, 127.2, 129.8 (2), 134.2 (q, J530.5 Hz), 148.7, 162.2.
3-Iodo-2-propylquinoline 5 tert-Butyllithium (1.5 M in pentane, 35.5
ml) was slowly added at 278 °C to a stirred solution of iodopropane (5.1 g,
30 mmol) in ether. The mixture was stirred 30 min at this temperature and al-
lowed to warm to 0 °C for 1 h. The solution was then cooled at 278 °C and
3-aminoquinoline (1.44 g, 10 mmol) in ether (10 ml) was slowly added. After
stirring 24 h at ambient temperature, the solution was quenched by the addi-
tion of saturated aqueous NH4Cl. After extraction (CHCl3), the solution was
dried and concentrated. The crude product was subjected to chromatography
to give 3-amino-2-propylquinoline (1.16 g, 60%). This latest compound
(1.12 g) was dissolved in acetic acid (18 ml) at 0 °C and sodium nitrite (1.48
g, 21.5 mmol) in H2O (10 ml) then potassium iodide (3.57 g, 21.5 mmol) in
H2O (15 ml) were added to the mixture. After 2 h, the solution was treated
with NaOH (1 N, 30 ml) and extracted with dichloromethane, then dried.
After evaporation, the residue was purified by silica gel column chromatog-
raphy to give 5 (1.02 g, 57%).
1H-NMR (CDCl3) d : 1.00 (3H, t, J57.4 Hz), 1.75 (2H, m), 3.00 (2H, t,
J57.4 Hz), 7.35 (1H, m), 7.55 (2H, m), 7.90 (1H, d, J58.4 Hz), 8.45 (1H, s).
13C-NMR (CDCl3) d : 14.1, 22.4, 43.6, 93.4, 126.2, 126.4, 128.2, 128.8,
129.8, 146.2, 147.0, 162.0.
2-Propyl-3-trifluoromethylquinoline 1f Under argon, 0.80 g (2.69
mmol) of 5, 1.27 g (8.08 mmol) of methyl 2-chloro-2,2-difluoroacetate, 0.84
g (4.40 mmol) of CuI and 0.255 g (4.39 mmol) of KF were stirred in DMF at
120 °C for 8 h. The resulting solution was poured into water, extracted with
dichloromethane and dried. After evaporation, the residue was purified by
silica gel column chromatography to give 1f (0.37 g, 57%).
1H-NMR (CDCl3) d : 0.95 (3H, t, J57.5 Hz), 1.80 (2H, m), 2.95 (2H, t,
J57.5 Hz), 7.40 (1H, t, J57.8 Hz), 7.70 (2H, m), 8.00 (1H, d, J57.8 Hz),
8.30 (1H, s). 13C-NMR (CDCl3) d : 14.1, 22.9, 37.9, 122.7 (q, J528 Hz),
124.1 (q, J5273 Hz), 124.8, 126.9, 128.2, 128.8, 131.5, 134.9 (q, J56 Hz),
148.7, 159.2. 19F-NMR (CDCl3) d : 260.79 (CF3, s).
Trifluoromethyl-2-quinolinecarboxaldehydes 6 500 mg (2.3 mmol) of
trifluoromethylquinaldine 2 and SeO2 (0.38 g, 3.45 mmol) were stirred in
dioxane (10 ml) under reflux for 4 h. After cooling and filtration, the solution
was concentrated and the residue was purified on silica gel to give 6.
8-Trifluoromethyl-2-quinolinecarboxaldehyde 6a: 81%. 1H-NMR (CDCl3) d :
7.75 (1H, m), 8.10 (3H, m), 8.40 (1H, d), 10.20 (1H, s). 19F-NMR (CDCl3)
d : 260.28 (CF3, s).
6-Trifluoromethyl-2-quinolinecarboxaldehyde 6b: 75%. 1H-NMR (CDCl3)
d : 8.00 (1H, d, J58.6 Hz), 8.10 (1H, d, J58.6 Hz), 8.25 (1H, s), 8.40 (2H, t,
J58.6 Hz), 10.20 (1H, s). 19F-NMR (CDCl3) d : 262.93 (CF3, s). 
(E)-2-(Propen-1-yl)-trifluoromethylquinolines 7 To a 0 °C cooled so-
lution of ethyltriphenylphosphonium iodide (5.8 g, 13.86 mmol) in THF (20
ml) was added PhLi (1.8 M in cyclohexan/ether, 7.7 ml). The red ylide solu-
tion was stirred at 0 °C for 10 min then quinolinecarboxaldehydes 6 (1.5 g,
6.6 mmol) in THF (10 ml) were slowly added via syringe. The resulting mix-
ture was allowed to warm to 20 °C and stirred further for 24 h. The solution
was poured into water, extracted with dichloromethane and dried. After
evaporation of the solvent, the residue was purified by column chromatogra-
phy.
(E)-2-(Propen-1-yl)-8-trifluoromethylquinoline 7a: 53%. 1H-NMR (CDCl3)
d : 1.90 (3H, dd, J56.7 Hz, J51.6 Hz), 6.60 (1H, qd, J51.6 Hz, J513.2 Hz),
6.90 (1H, qd, J56.7 Hz, J513.2 Hz), 7.30 (2H, m), 7.75 (1H, d, J58.2 Hz),
7.90 (2H, m). 19F-NMR (CDCl3) d : 260.91 (CF3, s). 13C-NMR (CDCl3) d :
18.5, 119.9, 124.1, 124.3 (q, J5273.9 Hz), 127.0, 127.3 (q, J529 Hz), 127.8
(q, J55.3 Hz), 131.8, 131.9, 134.1, 136.1, 144.6, 156.7.
(E)-2-(propen-1-yl)-6-trifluoromethylquinoline 7b: 67%. 1H-NMR (CDCl3)
d : 1.90 (3H, dd, J56.5 Hz, 1.3 Hz), 6.60 (1H, qd, J51.3 Hz, J515.6 Hz),
6.80 (1H, qd, J56.5 Hz, J515.6 Hz), 7.40 (1H, d, J58.7 Hz), 7.70 (1H, dd,
J52.1 Hz, J58.7 Hz), 8.00 (3H, m). 19F-NMR (CDCl3) d : 262.30 (CF3, s).
13C-NMR (CDCl3) d : 18.6, 121.4, 124.0 (q, J5273 Hz), 125.2 (q, J55.6
Hz), 125.4 (q, J55.0 Hz), 126.9 (q, J529 Hz), 127.9, 130.2, 131.9, 134.4,
136.7, 149.1, 158.4.
2-Epoxypropyltrifluoromethylquinolines 8 Ethyldiphenylsulfonium
tetrafluoroborate13) (673 mg, 2.23 mmol) in CH3CN (10 ml), KOH (125 mg,
2.20 mmol) and water (31 mg, 1.74 mmol) were stirred for 20 min at ambient
temperature. Quinolinecarboxaldehyde 6 (400 mg, 1.86 mmol) in CH3CN
(10 ml) was then added to the resulting solution and stirred for 20 h at room
temperature. The reaction was quenched by the addition of water (50 ml),
and after phase separation, the aqueous layer was extracted several times
with dichloromethane. After evaporation of the solvent, the residue was pu-
rified by column chromatography to give 8.
cis-2-(2-Methyloxirane)-8-trifluoromethylquinoline 8a: 40%. 1H-NMR
(CDCl3) d : 1.50 (3H, d, J55.2 Hz), 3.20 (1H, qd, J52.1 Hz, J55.2 Hz), 3.90
(1H, d, J52.1 Hz), 7.25 (1H, d, J58.7 Hz), 7.50 (1H, t, J58.0 Hz), 7.90 (1H,
d, J58.0 Hz), 7.95 (1H, d, J58.0 Hz), 8.10 (1H, d, J58.7 Hz). 19F-NMR
(CDCl3) d : 260.30 (CF3, s). 13C-NMR (CDCl3) d : 17.8, 58.4, 60.4, 117.5,
122.0 (q, J529 Hz), 124.1 (q, J5275.5 Hz), 125.0, 128.0 (q, J55.9 Hz),
132.1 (2), 136.9, 147.1, 159.1.
trans-2-(2-Methyloxirane)-8-trifluoromethylquinoline 8a: 40%. 1H-NMR
(CDCl3) d : 1.10 (3H, d, J55.6 Hz), 3.40 (1H, m), 4.25 (1H, d, J54.5 Hz),
7.40 (2H, m), 7.90 (1H, d, J58.3 Hz), 7.95 (1H, d, J57.6 Hz), 8.10 (1H, d,
J58.3 Hz). 19F-NMR (CDCl3) d : 260.27 (CF3, s). 13C-NMR (CDCl3) d :
12.8, 55.5, 58.7, 119.9, 124.1 (q, J5 273 Hz), 124.9, 127.2 (q, J529 Hz),
127.8, 128.1 (q, J55.5 Hz), 132.1, 136.0, 144.2, 157.7.
cis-2-(2-Methyloxirane)-6-trifluoromethylquinoline 8b: 38%. 1H-NMR
(CDCl3) d : 1.55 (3H, d, J55.0 Hz), 3.25 (1H, qd, J52.0 Hz, J55.0 Hz), 4.00
(1H, d, J52.0 Hz), 7.40 (1H, d, J58.8 Hz), 7.80 (1H, dd, J52.1 Hz, J58.8
Hz), 8.20 (3H, m). 19F-NMR (CDCl3) d : 262.50 (CF3, s). 13C-NMR
(CDCl3) d : 17.8, 58.4, 60.1, 117.9, 124.0 (q, J5277 Hz), 125.5,126.7, 128.3
(q, J529 Hz), 130.1, 137.7, 148.5, 160.5.
trans-2-(2-Methyloxirane)-6-trifluoromethylquinoline 8b: 40%. 1H-NMR
(CDCl3) d : 1.10 (3H, d, J55.3 Hz), 3.40 (1H, qd, J54.4 Hz, J55.3 Hz),
4.25 (1H, d, J54.4 Hz), 7.40 (1H, d, J58.5 Hz), 7.80 (1H, dd, J58.7 Hz,
J52.0 Hz), 8.10 (3H, m). 19F-NMR (CDCl3) d : 262.62 (CF3, s). 13C-NMR
(CDCl3) d : 12.8, 55.3, 58.3, 120.3, 124.0 (q, J5272 Hz), 125.5 (2), 126.4,
128.3 (q, J528.5 Hz), 130.1, 136.8, 148.5, 159.1.
2-3,3,3-(Trifluoropropyl)-quinoline 9 tert-Butyllithium (1.5 M in pen-
tane, 7.5 ml) was slowly added at 278 °C to a stirred solution of 3-bromo-
1,1,1-trifluoropropane (1 g, 5.65 mmol) in ether (5 ml). The solution was
then stirred 30 min at 278 °C and allowed to warm to 0 °C for 1 h. The solu-
tion was cooled at 278 °C and quinoline (0.4 g, 3.1 mmol) in ether (5 ml)
was slowly added to the mixture. After stirring at ambient temperature for
24 h, the solution was quenched (NH4Cl), extracted (CHCl3) and dried, then
purified by silica gel column chromatography to give 9 (0.42 g, 60%).
1H-NMR (CDCl3) d : 2.75 (2H, m), 3.25 (2H, m), 7.30 (1H, d, J58.5 Hz),
7.50 (1H, t, J58.5 Hz), 7.75 (2H, m), 8.05 (1H, d, J58.5 Hz), 8.10 (1H, d,
J58.5 Hz). 19F-NMR (CDCl3) d : 266.64 (CF3, t). 13C-NMR (CDCl3) d :
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25.5 (q, J53 Hz), 31.4 (q, J529.6 Hz), 119.4, 122.5, 125.6, 126.8 (q, J5275
Hz), 128.3 (2), 129.5, 130.7, 141.6, 145.5.
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